Back
 ABB  Vol.13 No.9 , September 2022
Bioequivalence Study of Two Formulations of Telmisartan 40 mg Tablets in Healthy Adult Bangladeshi Subjects under Fasting Conditions
Abstract: Background: Telmisartan is a highly variable drug which is used to treat hypertension. This study compared to compare the bioavailability of two 40 mg Telmisartan tablets in adult and healthy Bangladeshi subjects. Materials and Method: This study was open label, randomized, laboratory blind, single dose, three periods, two treatments, three-sequence, partial-replicate, crossover and comparative oral bioavailability study. In this study, 18 Bangladeshi subjects were enrolled and 17 subjects were completed. Serial blood samples were collected up to 96 hours following drug administration. By using Liquid Chromatography Mass Spectrometry (LC-MS/MS) method, plasma concentrations of Telmisartan were determined. Results: The two formulations of Telmisartan were considered bioequivalent if 90% Confidence Interval (CI) fall within the range of 80.00% - 125.00% for AUC parameters and reference-scaled-average bioequivalence of 69.84% - 143.19% for Cmax. The 90% Confidence Interval for Cmax, AUC0-t & AUC0-∞ was found 84.88% - 107.79%, 89.76% - 109.55%, and 91.20% - 114.52%, respectively. Conclusion: According to rate and extent of absorption with the single dose of Reference Product (R): Micardis® 40 mg Tablet, under fasting conditions, a single dose of Telmisartan 40 mg Tablet is bioequivalent.
Cite this paper: Reza, A. , Tushi, S. , Sahana, N. , Bhowmik, U. , Majumder, A. and Akram, A. (2022) Bioequivalence Study of Two Formulations of Telmisartan 40 mg Tablets in Healthy Adult Bangladeshi Subjects under Fasting Conditions. Advances in Bioscience and Biotechnology, 13, 419-427. doi: 10.4236/abb.2022.139027.
References

[1]   Bakheit, A.H., Abd-Elgalil, A.A., Mustafa, B., Haque, A. and Wani, T.A. (2015) Telmisartan. Profiles of Drug Substances, Excipients and Related Methodology, 40, 371-429.
https://doi.org/10.1016/bs.podrm.2015.01.003

[2]   https://www.rxlist.com/micardis-drug.htm.

[3]   (2021) Telmisartan 40mg Tablets. Summary of Product Characteristics (SmPC)-(emc).
https://www.medicines.org.uk/emc/product/5386/smpc

[4]   (2020) MICARDIS20-40-80mg.
https://docs.boehringer-ingelheim.com/Prescribing%20
Information/PIs/Micardis%20Tabs/MICARDIS20-40-80mg.pdf

[5]   Deppe, S., Böger, R.H., Weiss, J. and Benndorf, R.A. (2010) Telmisartan: A Review of Its Pharmacodynamic and Pharmacokinetic Properties. Expert Opinion on Drug Metabolism & Toxicology, 6, 863-871.
https://doi.org/10.1517/17425255.2010.494597

[6]   Ponce-Navarrete, D., Cortés-Mendoza, A., López-Bojórquez, E., González-Bañuelos, J., Burke-Fraga, V. and González-de la Parra, M. (2015) Bioavailability of Two Different Tablet Formulations of Telmisartan of Two Different Strengths (40 mg and 80 mg) in Healthy Male Mexican Volunteers. Journal of Bioequivalence & Bioavailability, 7, 164-169.
https://doi.org/10.4172/jbb.1000233

[7]   Kang, W.Y., Seong, S.J., Ohk, B., Gwon, M.R., Kim, B.K., La, S., Kim, H.J., Cho, S., Yoon, Y.R., Yang, D.H. and Lee, H.W. (2018) Pharmacokinetic and Bioequivalence Study of a Telmisartan/S-Amlodipine Fixed-Dose Combination (CKD-828) Formulation and Coadministered Telmisartan and S-Amlodipine in Healthy Subjects. Drug Design, Development and Therapy, 12, 545-553.
https://doi.org/10.2147/DDDT.S156492

[8]   Oh, M., Park, S.E., Ghim, J.L., Choi, Y.K., Shim, E.J., Shin, J.G. and Kim, E.Y. (2017) Comparative Pharmacokinetics of a Fixed-Dose Combination vs Concomitant Administration of Telmisartan and S-Amlodipine in Healthy Adult Volunteers. Drug Design, Development and Therapy, 11, 3543-3550.
https://doi.org/10.2147/DDDT.S148534

[9]   Chae, D.W., Son, M., Kim, Y., Son, H., Jang, S.B., Seo, J.M., Nam, S.Y. and Park, K. (2015) Pharmacokinetics of a Telmisartan/Rosuvastatin Fixed-Dose Combination: A Single-Dose, Randomized, Open-Label, 2-Period Crossover Study in Healthy Korean Subjects. International Journal of Clinical Pharmacology and Therapeutics, 53, 883-889.
https://doi.org/10.5414/CP202412

[10]   U.S. Food and Drug Administration (FDA) (2010) Draft Guidance on Telmisartan.
https://www.accessdata.fda.gov/drugsatfda_docs/psg/Telmisartan_tabs_20850_RC5-08.pdf

[11]   European Medicines Agency (2010) Committee for Medicinal Products for Human Use (CHMP) Guideline on the Investigation of Bioequivalence. European Medicines Agency, London.
https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-
investigation-bioequivalence-rev1_en.pdf


[12]   Party, E.W. (2006) Committee for Medicinal Products for Human Use (CHMP) Guideline on Data Monitoring Committees. Statistics in Medicine, 25, 1639-1645.
https://doi.org/10.1002/sim.2585

 
 
Top